A detailed history of Schonfeld Strategic Advisors LLC transactions in Nuvalent, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 5,700 shares of NUVL stock, worth $584,763. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,700
Previous 16,083 64.56%
Holding current value
$584,763
Previous $1.21 Million 64.21%
% of portfolio
0.0%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$62.76 - $81.61 $651,637 - $847,356
-10,383 Reduced 64.56%
5,700 $432,000
Q1 2024

May 15, 2024

BUY
$72.35 - $88.99 $66,417 - $81,692
918 Added 6.05%
16,083 $1.21 Million
Q4 2023

Feb 14, 2024

BUY
$42.42 - $80.28 $643,299 - $1.22 Million
15,165 New
15,165 $1.12 Million
Q4 2022

Feb 14, 2023

BUY
$18.46 - $36.37 $285,631 - $562,753
15,473 New
15,473 $460,000

Others Institutions Holding NUVL

About Nuvalent, Inc.


  • Ticker NUVL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,977,800
  • Market Cap $4.41B
  • Description
  • Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferr...
More about NUVL
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.